Chandrasekhar Chilappa, MD
Rheumatology · North Kansas City, MONPI 1225041221
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,347 of the $1,657 with a category attached, or 81.3%. 18 manufacturers reported payments, led by AbbVie at 40.3% of the total. Reporting peaked in 2023 at $522 and has fallen 90.4% since, to $50 in 2025. That places this record below the midpoint for rheumatology clinicians in MO, where the typical reported total is $1,657.
Across 93 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$668
- Boston Scientific$231
- Boehringer Ingelheim$126
- Amgen$103
- Johnson & Johnson$99
- GSK$86
- plus $345 from 12 others
What the payments were for
- Food & beverage$1,34781%
- Education$31119%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $668 |
| Boston Scientific | 11 | $231 |
| Boehringer Ingelheim | 5 | $126 |
| Amgen | 6 | $103 |
| Johnson & Johnson | 1 | $99 |
| GSK | 6 | $86 |
| Mallinckrodt Hospital Products Inc. | 2 | $76 |
| Fresenius Kabi USA, LLC | 3 | $50 |
| Genentech USA, Inc. | 2 | $50 |
| Celltrion USA Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Tersera Therapeutics LLC | 1 | $25 |
| Novo Nordisk | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Novartis | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Endogastric Solutions, Inc | 2 | $10 |
How this compares
$1,657 in reported general payments places this provider in the 50th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 95 | $737,544 |
| Enbrel MiniEtanercept | 49 | $377,885 |
| Enbrel SureclickEtanercept | 21 | $180,029 |
| Xeljanz XrTofacitinib Citrate | 15 | $87,105 |
| XeljanzTofacitinib Citrate | 15 | $83,797 |
| Hydroxychloroquine Sulfate | 315 | $15,384 |
| Leflunomide | 151 | $8,252 |
| MethotrexateMethotrexate Sodium | 263 | $6,301 |
| Mycophenolate Mofetil | 25 | $4,709 |
| Gabapentin | 201 | $3,476 |
| Leucovorin Calcium | 33 | $3,036 |
| Sulfasalazine | 79 | $2,261 |
| Prednisone | 322 | $2,130 |
| Azathioprine | 42 | $1,342 |
| Cyclobenzaprine Hcl | 61 | $776 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in North Kansas City
- Lena SabihNorth Kansas City$4K
- Anne WinklerCarthage$1.6M
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Mark BoxKansas City$304K
- Sona KamatSaint Louis$268K
- Robert JacksonMemphis$152K
- Richard BrasingtonSaint Louis$100K
- Michael JosephJoplin$94K
- Ghaith NoaisehKansas City$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.